Screening with GenoType^® MTBDR plus shortens the time to MDR-TB treatment initiation but does not change outcomes

Int J Tuberc Lung Dis. 2023 Dec 1;27(12):949-951. doi: 10.5588/ijtld.23.0096.

Authors

A Mendoza-Ticona¹, C D Mitnick², G Obregón³, V Alarcón⁴

Affiliations

¹ Centro Médico Oscar Romero, Socios En Salud Sucursal Perú, Lima, Peru.
² Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA.
³ Instituto Nacional de Salud, Ministerio de Salud Perú, Lima.
⁴ Dirección de Redes Integradas de Salud de Lima Este (DIRIS Lima Este), Ministerio de Salud de Perú, Lima, Peru.

PMID: 38042965
DOI: 10.5588/ijtld.23.0096

No abstract available

MeSH terms

Antitubercular Agents / therapeutic use
Genotype
Humans
Isoniazid
Microbial Sensitivity Tests
Mutation
Mycobacterium tuberculosis*
Tuberculosis, Multidrug-Resistant* / diagnosis
Tuberculosis, Multidrug-Resistant* / drug therapy

Substances

Antitubercular Agents
Isoniazid